PMID- 25433580
OWN - NLM
STAT- MEDLINE
DCOM- 20150918
LR  - 20240330
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Print)
IS  - 0163-4984 (Linking)
VI  - 163
IP  - 1-2
DP  - 2015 Feb
TI  - Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total 
      Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1beta, IL-6, and MCP-1: a 
      Double-blind, Placebo-controlled Clinical Study.
PG  - 124-31
LID - 10.1007/s12011-014-0155-9 [doi]
AB  - Calcium fructoborate (CFB) has been reported as supporting healthy inflammatory 
      response. In this study, we assess the effects of CFB on blood parameters and 
      proinflammatory cytokines in healthy subjects. This was a randomized, 
      double-blinded, placebo-controlled trial. Participants received placebo or CFB at 
      a dose of 112 mg/day (CFB-1) or 56 mg/day (CFB-2) for 30 days. Glucose, total 
      cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), 
      triglycerides (TG), C-reactive protein (CRP), homocysteine, interleukin 1 beta 
      (IL-1beta), IL-6, and monocyte chemoattractant protein-1 (MCP-1) were determined 
      before and after supplementation. CFB-1 showed a reduction in blood levels of CRP 
      by 31.3 % compared to baseline. CFB-1 and CFB-2 reduced LDL levels by 9.8 and 
      9.4 %, respectively. CFB-1 decreased blood homocysteine by 5.5 % compared with 
      baseline, whereas CFB-2 did not have a significant effect. Blood levels of TG 
      were reduced by 9.1 and 8.8 % for CFB-1 and CFB-2, respectively. Use of both 
      CFB-1 and CFB-2 resulted in significantly reduced IL-6 levels, when compared 
      within and between groups. IL-1beta was reduced by 29.2 % in the CFB-1 group. 
      Finally, CFB-1 and CFB-2 reduced MCP-1 by 31 and 26 %, respectively. Our data 
      indicate that 30-day supplementation with 112 mg/day CFB (CFB-1) resulted in a 
      significant reduction of LDL, TG, TC, IL-1beta, IL-6, MCP-1, and CRP. HDL levels 
      were increased, when compared to baseline and placebo. These results suggest that 
      CFB might provide beneficial support to healthy cardiovascular systems by 
      positively affecting these blood markers (ClinicalTrials.gov, ISRCTN90543844; May 
      24, 2012 ( http://www.controlled-trials.com/ISRCTN90543844 )).
FAU - Rogoveanu, Otilia-Constantina
AU  - Rogoveanu OC
AD  - Department of Physical Medicine and Rehabilitation, University of Medicine and 
      Pharmacy of Craiova, Craiova, Romania.
FAU - Mogosanu, George Dan
AU  - Mogosanu GD
FAU - Bejenaru, Cornelia
AU  - Bejenaru C
FAU - Bejenaru, Ludovic Everard
AU  - Bejenaru LE
FAU - Croitoru, Octavian
AU  - Croitoru O
FAU - Neamtu, Johny
AU  - Neamtu J
FAU - Pietrzkowski, Zbigniew
AU  - Pietrzkowski Z
FAU - Reyes-Izquierdo, Tania
AU  - Reyes-Izquierdo T
FAU - Bita, Andrei
AU  - Bita A
FAU - Scorei, Iulia Daria
AU  - Scorei ID
FAU - Scorei, Romulus Ion
AU  - Scorei RI
LA  - eng
SI  - ISRCTN/ISRCTN90543844
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141130
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
RN  - 0 (Borates)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (IL1B protein, human)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Triglycerides)
RN  - 0 (calcium fructoborate)
RN  - 0 (low density lipoprotein triglyceride)
RN  - 30237-26-4 (Fructose)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Borates/*administration & dosage
MH  - C-Reactive Protein/*metabolism
MH  - Chemokine CCL2/*blood
MH  - Cholesterol/*blood
MH  - Double-Blind Method
MH  - Female
MH  - Fructose/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Interleukin-1beta/*blood
MH  - Interleukin-6/*blood
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Triglycerides/*blood
PMC - PMC4297309
EDAT- 2014/12/01 06:00
MHDA- 2015/09/19 06:00
PMCR- 2014/11/30
CRDT- 2014/12/01 06:00
PHST- 2014/09/09 00:00 [received]
PHST- 2014/10/02 00:00 [accepted]
PHST- 2014/12/01 06:00 [entrez]
PHST- 2014/12/01 06:00 [pubmed]
PHST- 2015/09/19 06:00 [medline]
PHST- 2014/11/30 00:00 [pmc-release]
AID - 155 [pii]
AID - 10.1007/s12011-014-0155-9 [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 2015 Feb;163(1-2):124-31. doi: 10.1007/s12011-014-0155-9. 
      Epub 2014 Nov 30.